TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05203302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modulation Detection Threshold (MDT) and Gap Detection Tasks
Description: AIM 1 - MDT will be set at 150 Hz. Testing will be conducted in soundfield in a sound booth at 60 dB Sound Pressure Level (SPL) while the participant listens with both implants adjusted to user setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modulation Detection Threshold (MDT) and Gap Detection Tasks
Description: AIM 1 - MDT will be set at 150 Hz. Testing will be conducted in soundfield in a sound booth at 60 dB Sound Pressure Level (SPL) while the participant listens with both implants adjusted to user setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modulation Detection Threshold (MDT) and Gap Detection Tasks
Description: AIM 1 - MDT will be set at 150 Hz. Testing will be conducted in soundfield in a sound booth at 60 dB Sound Pressure Level (SPL) while the participant listens with both implants adjusted to user setting.
Study: NCT01530451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: one tab OD
Study: NCT01915472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMMU 130
Description: This is a Phase II, open-label study of IMMU-130 administered every 14 days for a period of 24 weeks to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
Study: NCT02372500

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: Sugar free chewing gum
Study: NCT01465529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OligoG CF-5/20
Description: 6% OligoG CF-5/20 in water

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% NaCl in water
Study: NCT01493232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: buccalized occlusion
Description: Making a set of complete denture with new Buccalized Occlusion that is different from current occlusion in my country. In this type just buccal casps of mandibular teeth will be connect to the central fossa of maxillary teeth and lingual casps have not contact.
Study: NCT05203302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound coding strategy.
Description: Aim3 - Spectral-temporally modulated ripple test (SMRT), Quick Spectral Modulation Detection (QSMD), Modulation Detection, Gap Detection. CNC words will be set in quiet and Az-Bio/BabyBio sentences in quiet and multi-talker babble (+10 and +5 dB SNR) using both the subject's clinical map and the new reduced channels map. Tests will be presented in the soundfield at 60 dB SPL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound coding strategy.
Description: Aim3 - Spectral-temporally modulated ripple test (SMRT), Quick Spectral Modulation Detection (QSMD), Modulation Detection, Gap Detection. CNC words will be set in quiet and Az-Bio/BabyBio sentences in quiet and multi-talker babble (+10 and +5 dB SNR) using both the subject's clinical map and the new reduced channels map. Tests will be presented in the soundfield at 60 dB SPL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound coding strategy.
Description: Aim3 - Spectral-temporally modulated ripple test (SMRT), Quick Spectral Modulation Detection (QSMD), Modulation Detection, Gap Detection. CNC words will be set in quiet and Az-Bio/BabyBio sentences in quiet and multi-talker babble (+10 and +5 dB SNR) using both the subject's clinical map and the new reduced channels map. Tests will be presented in the soundfield at 60 dB SPL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric-only spectral resolution
Description: Aim 1- Spectral resolution will be tested using frequency allocations consisting of the full default clinical range as well as the subject's clinical frequency allocation if they differ. For Hybrid electrode users in which electrode contacts are closer in proximity in the cochlea, maps with a frequency allocation of 938-7938 Hz will also be tested in that it will closely approximate the frequency spacing of a Nucleus Contour Advance electrode array. Spectral resolution will be measured with three repetitions of the SMRT and one repetition of the QSMD test. Testing will be presented at 60 dB SPL in the soundfield with the acoustic ear plugged and muffed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric-only spectral resolution
Description: Aim 1- Spectral resolution will be tested using frequency allocations consisting of the full default clinical range as well as the subject's clinical frequency allocation if they differ. For Hybrid electrode users in which electrode contacts are closer in proximity in the cochlea, maps with a frequency allocation of 938-7938 Hz will also be tested in that it will closely approximate the frequency spacing of a Nucleus Contour Advance electrode array. Spectral resolution will be measured with three repetitions of the SMRT and one repetition of the QSMD test. Testing will be presented at 60 dB SPL in the soundfield with the acoustic ear plugged and muffed.
Study: NCT01473134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxford Cementless Partial Knee
Description: Oxford Partial Knee applied without bone cement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxford Cemented Partial Knee
Description: Oxford Partial Knee applied with bone cement.
Study: NCT04303767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium phosphate
Description: varnish containing calcium and phospate ions which act as a source for tooth remineralization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic restorative treatment
Description: excavation of dental caries and restoring with light cured Glass Ionomer Restoration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment
Description: excavation of dental caries and restoring with light cured Glass Ionomer Restoration
Study: NCT02290132

Intervention type: DRUG
Intervention: Rabbit Anti-human Thymocyte Globulin (ATG)
Description: The conditioning regimen in this study consisted of Rabbit antithymocyte globulin (ATG 2.5 mg/kg×4 days) , total-body irradiation (10 Gy in five fractions), cyclophosphamide (60 mg/kg×2 days) and etoposide or teniposide (30-40mg/kg) .
Study: NCT04367012

Intervention type: OTHER
Intervention: Abdominal Ultrasound
Description: patient in supine position and external carotid artery was examined to meausre the intima using US .Machine GE logic FB inear probe10Mhz.and intimal media thickness mean =10mm

Intervention type: OTHER
Intervention: Abdominal Ultrasound
Description: patient in supine position and external carotid artery was examined to meausre the intima using US .Machine GE logic FB inear probe10Mhz.and intimal media thickness mean =10mm
Study: NCT02043457

Intervention type: OTHER
Intervention: phenotyping
Study: NCT06604650

Intervention type: BEHAVIORAL
Intervention: Active older Adults
Description: The program entails one-hour sessions two or three times per week including aerobic workout, strength training, balance and flexibility exercise delivered online or in-person. Miami-Dade Parks and Recreation is the sponsor of the Active Older Adults prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Active Older Adults study.
Study: NCT06590571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRAcelet™
Description: The group using TRAcelet™ after transradial angiography/intervention receives 2 hours and 15 minutes of compression from the device, followed by 3 stepwise releases every 15 minutes. There are two sizes of TRAcelet™ available, large and medium. Assuming that a Korean adult's wrist size is smaller than that of the Western population, we used a medium-sized TRAcelet™.

Intervention type: OTHER
Group type: OTHER
Intervention: Gauze pad
Description: Patients received radial artery compression by a gauze pad fastened with 3M™ Durapore™ surgical tape. An additional one hour of compression was applied when incomplete hemostasis or hematoma was identified.
Study: NCT06597552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training Group
Description: Inspiratory muscle training (IMT) was performed using the Threshold IMT device using the threshold loading method. The IMT was administered to the patients in the training group at 30% of the MIP value, 5 days a week, twice a day, for 15 minutes for 8 weeks. The patients in the training group were called for a check-up once a week and the MIP value was re-evaluated. The training workload for that week was determined by taking 30% of the new measured MIP value.~During the training, the patients were asked to sit with their upper body (shoulders and upper chest) in a relaxed position, and after the nose was closed with the clip, the mouthpiece of the device was tightly closed with the lips. While in this position, the patient was asked to inhale and exhale 5 times into the device, then remove the device from their mouth and listen for 5 breaths, and continue this cycle for 15 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The training intensity of the control group was given at the lowest load (9 cm H2O) for 8 weeks, five days a week, twice a day for 15 minutes. To eliminate the effect of learning, the MIP measure of the control group was measured once a week, but the intensity of the training was not increased during the 8 weeks.
Study: NCT06604247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral therapy for insomnia (CBT-I)
Description: Cognitive Behavioral Therapy for Insomnia includes evaluation and orientation; data acquisition and delivery of sleep restriction therapy \&amp; stimulus control instructions; review of sleep hygiene; cognitive therapy \[decatastrophization\]; managing nonadherence and relapse prevention), and, finally, the final sessions will be largely focused on time-in-bed titration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral therapy for insomnia (CBT-I)
Description: Cognitive Behavioral Therapy for Insomnia includes evaluation and orientation; data acquisition and delivery of sleep restriction therapy \&amp; stimulus control instructions; review of sleep hygiene; cognitive therapy \[decatastrophization\]; managing nonadherence and relapse prevention), and, finally, the final sessions will be largely focused on time-in-bed titration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral therapy for insomnia (CBT-I)
Description: Cognitive Behavioral Therapy for Insomnia includes evaluation and orientation; data acquisition and delivery of sleep restriction therapy \&amp; stimulus control instructions; review of sleep hygiene; cognitive therapy \[decatastrophization\]; managing nonadherence and relapse prevention), and, finally, the final sessions will be largely focused on time-in-bed titration.
Study: NCT02677454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitor
Study: NCT04025112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo®Power
Description: Randomized patients will be offered rehabilitation robotic using Armeo®Power from Hocoma, the first robotic arm exoskeleton for integrated arm and hand therapy, during one month, three times a week, totalizing 12 sessions of 45 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation protocol
Description: Randomized patients will be offered the conventional rehabilitation protocol from Barretos Cancer Hospital during one month, three times a week, totalizing 12 sessions of 45 minutes.
Study: NCT04253067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active fCO2 laser treatment
Description: The laser probe is inserted into the vagina. Laser treatment is delivered at 6 points at each level of the vaginal wall (12, 2, 4, 6, and 10 o'clock positions). Delivery begins at the most proximal and the probe is retracted by 1 cm and another row of laser treatments are delivered. The number of levels is determined by the patient's vaginal length.
Study: NCT06604247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral therapy for insomnia (CBT-I)
Description: Cognitive Behavioral Therapy for Insomnia includes evaluation and orientation; data acquisition and delivery of sleep restriction therapy \&amp; stimulus control instructions; review of sleep hygiene; cognitive therapy \[decatastrophization\]; managing nonadherence and relapse prevention), and, finally, the final sessions will be largely focused on time-in-bed titration.
Study: NCT06592690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atrial pacing support
Description: Use a pacing mode with atrial pacing including a rate-resposive sensor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Atrial tracking pacing mode
Description: A pacing mode which allows sensing of intrinsic sinus rhythm as much as possible to avoid unnecessary atrial pacing is the preferred programming in patients with CRT without atrial pacing indication. VDD pacing mode met these criteria.
Study: NCT02681523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Study: NCT02711891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Following lance one, 0.2 grams of loperamide 5% gel was applied from a sterile syringe to the participants previous lance site within an 8 mm diameter circular plastic mold. The loperamide gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The loperamide gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug, placebo gel
Description: Following lance one, 0.2 grams of gel alone was applied to the participants previous lance site within an 8mm diameter circular plastic mold. The gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing left in place for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The placebo gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
Study: NCT04088890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 500 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 500 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD22 CAR
Description: Autologous T cells transduced with lentiviral vector (CD22.BB.Z) Chimeric Antigen Receptor (CD22 CAR). Autologous CD22 CAR T cells will be administered intravenously at Dose Level 1 in subjects with ALL. Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) in subjects with aggressive B-cell NHL to determine MTD/RP2D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD22 CAR
Description: Autologous T cells transduced with lentiviral vector (CD22.BB.Z) Chimeric Antigen Receptor (CD22 CAR). Autologous CD22 CAR T cells will be administered intravenously at Dose Level 1 in subjects with ALL. Autologous CD22-CAR T cells will be administered in 3 escalating doses (Dose Level 1, 2, and 3) in subjects with aggressive B-cell NHL to determine MTD/RP2D
Study: NCT03811821

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: The participant will learn how to improve strength and rectal sensation during five (5) - six (6) visits each lasting 60 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Injection
Description: The participant will have a bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.
Study: NCT04253067

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham fCO2 laser treatment
Description: The laser probe is inserted into the vagina. The laser will remain in standby mode during the treatment preventing laser exposure. The treatment will appear to be the same as the active treatment with the probe starting at the most proximal and following the same 6 points of treatment delivery. The probe is retracted in the same manner and another row of treatment is simulated. The machine maintains a low humming noise while in standby mode. No active laser treatment is delivered.
Study: NCT00662935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: setting-up of an electrode in deep brain
Description: deep brain stimulation of the postero-inferoir hypothalamus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: setting-up of an electrode in deep brain
Description: deep brain stimulation of the postero-inferoir hypothalamus
Study: NCT03699085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED-LINC
Description: ED-LINC will include 1) A brief negotiated interview at the bedside with an emphasis on motivation to link to services 2) Pharmacotherapy including a discussion of opioid safety, take-home naloxone and initiation of buprenorphine from the ED for participants that are interested and eligible; 3) Longitudinal care management which will proceed for 3-months; and 4) Care plan in the Emergency Department Information Exchange (EDIE) system. This will be coupled with a study cell phone and a weekly supervisory case conference which is consistent with collaborative care principles.
Study: NCT04224571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib Injection
Description: Bortezomib: patients with BM relapsed, add for 4 doses on D1,4,7, 11 in induction; dosage 1.3 mg/m2/dose as per parenteral;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab injection
Description: Add rituximab in patients with CD20 positive ALL, rituximab: 6 doses of on D8,11of induction, D1,15 of consolidation1 and 2 with dosage 375 mg/m2 as parenteral (Terminated in Oct 2020)
Study: NCT00158860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Description: 1g once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03235284

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training
Study: NCT03904849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: Cannabidiol oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution
Study: NCT04522765

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of 24 hour blood pressure and arterial stiffness
Description: Assessment of 24 hour blood pressure and arterial stiffness using Mobil-o-graph device

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of 24 hour blood pressure and arterial stiffness
Description: Assessment of 24 hour blood pressure and arterial stiffness using Mobil-o-graph device

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of 24 hour blood pressure and arterial stiffness
Description: Assessment of 24 hour blood pressure and arterial stiffness using Mobil-o-graph device

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of 24 hour blood pressure and arterial stiffness
Description: Assessment of 24 hour blood pressure and arterial stiffness using Mobil-o-graph device

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of 24 hour blood pressure and arterial stiffness
Description: Assessment of 24 hour blood pressure and arterial stiffness using Mobil-o-graph device

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of 24 hour blood pressure and arterial stiffness
Description: Assessment of 24 hour blood pressure and arterial stiffness using Mobil-o-graph device
Study: NCT00399308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celaderm (Frozen Cultured Epidermal Allograft)
Description: Four biweekly applications of Celaderm plus compression therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celaderm (Frozen Cultured Epidermal Allograft)
Description: Four weekly applications of Celaderm plus compression therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control (compression bandaging)
Description: Multi-layer compression bandaging
Study: NCT03874338

Intervention type: DRUG
Intervention: Colchicine Pill
Description: Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.

Intervention type: DRUG
Intervention: Colchicine Pill
Description: Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.
Study: NCT05882591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).
Description: Posteromedial Tibiofemoral Incongruence (PMTFI) Treatment by the means of published technique (reference nr 1).
Study: NCT02027155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR09 solution
Description: moderate levels of sedation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AR09 solution
Description: moderate levels of sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Sterile Saline, USP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Sterile Saline, USP